Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNCX Quince Therapeutics, Inc.

Post-Mkt 03-04 18:29:42 EST

0.1040

+0.0088

+9.24%

盘后0.1033

-0.0007-0.67%

18:29 EST

High0.1098	Low0.0894	Vol32.76M
Open0.0967	D1 Closing0.0952	Amplitude21.43%
Mkt Cap5.79M	Tradable Cap5.15M	Total Shares55.68M
T/O3.44M	T/O Rate66.11%	Tradable Shares49.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNCX","market":"US","secType":"STK","nameCN":"Quince Therapeutics, Inc.","latestPrice":0.104,"timestamp":1772658000000,"preClose":0.0952,"halted":0,"volume":32763600,"hourTrading":{"tag":"盘后","latestPrice":0.1033,"preClose":0.104,"latestTime":"18:29 EST","volume":4907295,"amount":553316.9932111499,"timestamp":1772666967996,"change":-0.0007,"changeRate":-0.006731,"amplitude":0.2125},"delay":0,"changeRate":0.09243697478991583,"floatShares":49558000,"shares":55681490,"eps":-1.209231,"marketStatus":"Post-Mkt","change":0.0088,"latestTime":"03-04 18:29:42 EST","open":0.0967,"high":0.1098,"low":0.0894,"amount":3438387.46926,"amplitude":0.214286,"askPrice":0.1055,"askSize":200,"bidPrice":0.1018,"bidSize":99,"shortable":0,"etf":0,"ttmEps":-1.209231,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772672400000},"marketStatusCode":4,"adr":0,"listingDate":1557374400000,"exchange":"NASDAQ","adjPreClose":0.0952,"preHourTrading":{"tag":"盘前","latestPrice":0.0947,"preClose":0.0952,"latestTime":"09:29 EST","volume":802858,"amount":75258.42042126799,"timestamp":1772634540396,"change":-0.0005,"changeRate":-0.005252,"amplitude":0.079832},"postHourTrading":{"tag":"盘后","latestPrice":0.1033,"preClose":0.104,"latestTime":"18:29 EST","volume":4907295,"amount":553316.9932111499,"timestamp":1772666967996,"change":-0.0007,"changeRate":-0.006731,"amplitude":0.2125},"volumeRatio":0.666912,"impliedVol":2.862,"impliedVolPercentile":0.9004},"requestUrl":"/m/hq/s/QNCX/wiki","defaultTab":"wiki","newsList":[{"id":"2611026138","title":"What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2611026138","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611026138?lang=en_us&edition=fundamental","pubTime":"2026-02-13 14:51","pubTimestamp":1770965460,"startTime":"0","endTime":"0","summary":"Quince Therapeutics shares surged 53% after hours Thursday following the engagement of LifeSci Capital as financial advisor amid restructuring and strategic plans.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/13/Financial-Graph-With-Uptrend-Line-Techno.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/13/Financial-Graph-With-Uptrend-Line-Techno.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/02/50602390/what-sparked-quince-therapeutics-qncx-stock-to-rise-53-after-hours","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/02/50602390/what-sparked-quince-therapeutics-qncx-stock-to-rise-53-after-hours","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["RSI","BK4150","QNCX","BK4139"],"gpt_icon":1},{"id":"2611939906","title":"NASD Most Active Issues","url":"https://stock-news.laohu8.com/highlight/detail?id=2611939906","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611939906?lang=en_us&edition=fundamental","pubTime":"2026-02-13 06:43","pubTimestamp":1770936180,"startTime":"0","endTime":"0","summary":"ProShares UltraPro QQQ      TQQQ   129,420,663     48.26    -3.14     -6.11. Direxion TSLA Bull 2X       TSLL    81,344,410     15.89    -0.91     -5.42. Invesco QQQ Trust I          QQQ    80,550,698    600.64   -12.47     -2.03. Direxion Dly TSLA Br 1X     TSLS    63,996,524      5.44     0.16      2.93. Defiance Dly Tgt 2x Lg      MSTX    63,572,529      2.09    -0.11     -5.00. iShares Bitcoin Trust ETF   IBIT    61,884,048     37.05    -1.24     -3.24. ProSh UltraPro Shrt QQQ     SQQQ    61,012,817     73.10     4.22      6.13","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4529","LU0823414478.USD","LU0345769128.USD","LU1852331112.SGD","LU2045819591.USD","LU2360106780.USD","LU2506951875.HKD","SG9999001135.SGD","PTIR","HODU","SQQQ","LU1551013425.SGD","LU2264538146.SGD","IE00BJLML261.HKD","QNCX","LU1244550221.USD","IE00BWXC8680.SGD","LU0672654240.SGD","LU2362541273.HKD","LU2506952170.USD","LU2552382215.SGD","04333","BK4023","IE00BQXX3D17.EUR","LU2362541513.USD","BK4612","LU1316542783.SGD","LU0210637038.USD","NFLW","LU2237443978.SGD","LU0353189680.USD","BK4613","TSLT","LU0321505868.SGD","LU2089985449.USD","SG9999013460.SGD","LU0353189763.USD","LU2860962120.EUR","LU0234572021.USD","SG9999013478.USD","LU1880398554.USD","LU1069344957.HKD","PLTD","IE00BQXX3C00.GBP","LU1066051811.HKD","IE00B19Z8W00.USD","LU0198837287.USD","BK4551","LU1267930813.SGD","BK4020","LU0234570918.USD","BK4561","IE00B42XCP33.USD","LU1823568750.SGD","IE00B1XK9C88.USD","LU2552382058.USD","LU0210536198.USD","LU1674673428.USD","SG9999002414.USD","BK4539","TSLQ","NFLP","LU2417539215.USD","LU1064131342.USD","TSDD","LU0642271901.SGD","LU0345770993.USD","BK4604","LU0889566641.SGD","HOOW","LU2237443382.USD","LU2461242641.AUD","TESL","SGXZ23171101.USD","IE00BVYPNW00.USD","07766","LU1429558221.USD","BK4574","LU1032955483.USD","BK4507","LU1366192091.USD","TSLZ","IE00BGHQF631.EUR","BK4605","IE00BDGV0183.EUR","IE00B19Z9505.USD","LU2087621335.USD","LU1839511570.USD","LU0323591593.USD","LU0053666078.USD","LU0823417737.USD","LU1599440770.SGD","LU0345770308.USD","LU1066051225.USD","BTC.USD.CC","TSLG","BK4581","LU0689472784.USD","LU0203347892.USD","LU0942090050.USD","LU1435385759.SGD","LU1861215975.USD","TSLP","TSLR","LU1585245621.USD","LU0203202063.USD","LU2756315664.SGD","LU1221951046.USD","BK4524","BK4141","LU2462157665.USD","LU2420271590.USD","LU1629891620.HKD","BK4535","LU2750360641.GBP","LU2456880835.USD","BK4547","LU1235294995.USD","SG9999015945.SGD","BK4593","NVDA","LU2750360997.AUD","BK4516","LU0097036916.USD","LU2087625088.SGD","PLYY","LU1232071149.USD","PLTZ","TQQQ","LU1196500208.SGD","LU0719512351.SGD","SGXZ58947870.SGD","BK4527","LU1059921491.USD","SG9999002604.SGD","BK4108","LU0731783394.SGD","LU2213496289.HKD","LU1221951129.SGD","FSLY","LU0823411888.USD","LU1035775433.USD","LU1989764664.SGD","PLTU","HOOZ","LU2249611893.SGD","LU0820561818.USD","SG9999004303.SGD","SGXZ51526630.SGD","LU0348723411.USD","LU2471134952.CNY","IE00BKPKM429.USD","LU0203345920.USD","LU0320765646.SGD","IE00B1BXHZ80.USD","IE00BSNM7G36.USD","LU2286300806.USD","CRSH","LU0127658192.USD","LU1894683264.USD","TSYY","NFXL","SG9999001440.SGD","LU2896262040.SGD","LU2471134523.USD","IE00BFMHRM44.USD","IE00BK4W5M84.HKD","TSLW","LU0868494617.USD","LU0210533765.USD","LU2361044949.HKD","LU0708995401.HKD","BK4532","BK4230","BK4543","IE00BFXG1179.USD","LU0256863902.USD","QQQI","ROBN","CSCO","LU2237443465.HKD","LU1674673691.USD","SG9999001424.SGD",".IXIC","BK4598","PLOO","BK4533","LU0321505439.SGD","LU0792757196.USD","LU2237957811.SGD","TSLL","LU1861220033.SGD","BK4550","HOOX","PLTY","IE00B3T34201.USD","IE0034235303.USD","LU0079474960.USD","BK4579","BK4601","LU1066051498.USD","LU1066053197.SGD","LU2357305700.SGD","TSLI","NFXS","LU2125910500.SGD","BK4122","LU2237443549.SGD","LU2023250330.USD","LU1720051108.HKD","LU0106261372.USD","LU0964807845.USD","IE00BKVL7J92.USD","LU0786609619.USD","IE00BZ1G4Q59.USD","BK4575","LU1506573853.SGD","IE00BQXX3F31.USD","BK4592","LU2602419157.SGD","IE00BVYPNV92.GBP","IE00BK4W5L77.USD","IE00B894F039.SGD","LU2326559502.SGD","SG9999015986.USD","LU2931357623.SGD","SG9999002679.SGD","HOYY","IE00B19Z8X17.USD","LU2552382132.HKD","LU0109391861.USD","LU1244550494.USD","LU1145028129.USD","BK4585","LU1929549753.HKD","LU1720051017.SGD","LU1242518857.USD","LU1778281490.HKD","LU1861559042.SGD","IE000M9KFDE8.USD","LU0098860793.USD","SG9999015978.USD","LU2506951958.HKD","LU0316494557.USD","LU0823417653.USD","BK4525","LU2506952097.USD","LU1162221912.USD","LU0077335932.USD","SG9999002224.SGD","LU0882574139.USD","LU2360107168.USD","BK4515","SG9999013486.USD","HOOY","LU1548497426.USD","LU2403377893.USD","LU1814569148.SGD","LU0868494708.USD","LU1861558580.USD","LU1914381329.SGD","SG9999015952.SGD","LU2063271972.USD","SG9999002406.SGD","BK4099","SG9999002620.SGD","LU1839390173.USD","04335","IE00B3PB1722.GBP","LU2237957902.USD","SG9999002232.USD","LU1883839398.USD","LU1244550577.SGD","BK4548","LU2361044865.SGD","LU2471134796.USD","LU2237443622.USD","LU2756315318.SGD","IE00B19Z9Z06.USD","LU0274383776.USD","LU1267930730.SGD","LU0320765059.SGD","LU0082616367.USD","LU0979878070.USD","LU0417517546.SGD","LU1894683348.USD","NFLY","BK4511","TSLO","TSLY","TSLS","BK4594","LU2250418816.HKD","LU0256863811.USD","TSL","BK4602","BK4127","LU0203201768.USD","LU1988902786.USD","LU2108987350.USD","PLT","LU2237443895.HKD","LU1880398471.USD","LU0466842654.USD","PLTA","BK4554","PLTW","BK4555","LU1242518931.SGD","SGXZ99366536.SGD","BK4560","BK4534","LU2361045086.USD","IE00BZ9MQY76.HKD","LU2471134879.HKD","LU2247934214.USD","LU2148611432.USD","LU1551013342.USD","LU1127390331.HKD","LU0532188223.SGD","LU0820562030.AUD","LU0820561909.HKD","LU1430594728.SGD","BK4022","LU2236285917.USD","LU2290526834.HKD","LU0215105999.USD","NFLU","HOOI","LU2543165471.USD","BK4588","LU2362540622.SGD","LU0225283273.USD","SGXZ81514606.USD","LU0345769631.USD","LU0006306889.USD","LU0056508442.USD","BK4587","LU0950375773.USD","LU0441851309.USD","BK4566","LU1571399168.USD","PLTG","LU0943347566.SGD","LU1046421795.USD","IE00B19Z9P08.USD","TSII","BK4512","HOOG","SG9999006266.SGD","LU0081259029.USD"],"gpt_icon":1},{"id":"2610507947","title":"BRIEF-Quince Therapeutics - On Feb 9, Engaged Lifesci Capital For Strategic Alternatives - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2610507947","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610507947?lang=en_us&edition=fundamental","pubTime":"2026-02-12 19:14","pubTimestamp":1770894862,"startTime":"0","endTime":"0","summary":"BRIEF-Quince Therapeutics - On Feb 9, Engaged Lifesci Capital For Strategic Alternatives - SEC FilingFeb 12  - Quince Therapeutics Inc QNCX.O:QUINCE THERAPEUTICS - ON FEB 9, ENGAGED LIFESCI CAPITAL FOR STRATEGIC ALTERNATIVES - SEC FILINGQUINCE THERAPEUTICS - PLANS TO FOCUS ON REVERSE MERGER - SEC FILINGQUINCE THERAPEUTICS - LEAD DRUG CANDIDATE EDSP FAILS IN NEAT TRIAL - SEC FILINGQUINCE THERAPEUTICS: DO NOT HAVE RESOURCES TO PURSUE FURTHER OPERATIONS ON LEAD DRUG CANDIDATE, EDSPSource text: []Further company coverage: QNCX.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z80G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2610947895","title":"Quince Therapeutics - Plans to Focus on Reverse Merger - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2610947895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610947895?lang=en_us&edition=fundamental","pubTime":"2026-02-12 19:09","pubTimestamp":1770894548,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z80G4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2610947323","title":"Quince Therapeutics: Do Not Have Resources to Pursue Further Operations on Lead Drug Candidate, Edsp","url":"https://stock-news.laohu8.com/highlight/detail?id=2610947323","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610947323?lang=en_us&edition=fundamental","pubTime":"2026-02-12 19:09","pubTimestamp":1770894548,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z80G4:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2610896947","title":"Quince Therapeutics - on Feb 9, Engaged Lifesci Capital for Strategic Alternatives - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2610896947","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610896947?lang=en_us&edition=fundamental","pubTime":"2026-02-12 19:09","pubTimestamp":1770894548,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z80G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2610294734","title":"Quince Therapeutics - Lead Drug Candidate Edsp Fails in Neat Trial - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2610294734","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610294734?lang=en_us&edition=fundamental","pubTime":"2026-02-12 19:09","pubTimestamp":1770894548,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z80G4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2610968220","title":"Quince Therapeutics Stock Extends Rally On Strategic Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2610968220","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610968220?lang=en_us&edition=fundamental","pubTime":"2026-02-12 02:59","pubTimestamp":1770836340,"startTime":"0","endTime":"0","summary":"Quince Therapeutics is soaring again on Wednesday as the company has engaged LifeSci Capital to explore strategic alternatives aimed at maximizing shareholder value.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/11/Defense--Biotech-Favored.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/11/Defense--Biotech-Favored.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/02/50555353/quince-therapeutics-stock-extends-rally-on-strategic-review","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/02/50555353/quince-therapeutics-stock-extends-rally-on-strategic-review","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["SMA","BK4139","BK4217","BK4007","QNCX","BK4539","LENZ"],"gpt_icon":0},{"id":"2610628881","title":"Why Is Quince Therapeutics Stock (QNCX) Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2610628881","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610628881?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:58","pubTimestamp":1770728298,"startTime":"0","endTime":"0","summary":"Quince Therapeutics stock was up on Tuesday after it announced plans to explore strategic alternatives.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-quince-therapeutics-stock-qncx-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-quince-therapeutics-stock-qncx-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2610893641","title":"Why Is Quince Therapeutics Stock Soaring Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2610893641","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610893641?lang=en_us&edition=fundamental","pubTime":"2026-02-10 18:58","pubTimestamp":1770721080,"startTime":"0","endTime":"0","summary":"Quince Therapeutics, Inc.  stock is up during Tuesday’s premarket session as the company has engaged LifeSci Capital to serve as its exclusive financial advisor.The penny stock is trading higher on a robust session volume of 29.84 million versus the average volume of 2.92 million, according to Benzinga Pro data.Currently, Quince Therapeutics is trading 89.6% below its 20-day simple moving average  and 91.2% below its 100-day SMA, indicating significant weakness in the short to medium term. Over the past 12 months, shares have decreased by 90.91%, and they are positioned closer to their 52-week lows than highs, reflecting ongoing challenges for the company.The RSI is at 22.15, indicating that the stock is in oversold territory, which could suggest a potential for a rebound if buying interest increases. Meanwhile, the MACD is below its signal line, reinforcing the bearish pressure on the stock.The combination of oversold RSI and bearish MACD suggests mixed momentum, indicating that while","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/10/Close-Up-Computer-Display-With-Red-And-G.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/10/Close-Up-Computer-Display-With-Red-And-G.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/02/50502899/why-is-quince-therapeutics-stock-soaring-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/02/50502899/why-is-quince-therapeutics-stock-soaring-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LENZ","BK4217","BK4539","SMA","QNCX","BK4007","BK4139"],"gpt_icon":0},{"id":"2610066504","title":"Quince Therapeutics Engages LifeSci Capital to Pursue Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2610066504","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610066504?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:05","pubTimestamp":1770671117,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. has announced that it has engaged LifeSci Capital as its exclusive financial advisor to assist with its restructuring and the evaluation of strategic alternatives aimed at maximizing shareholder value. Potential options under consideration include partnerships, joint ventures, mergers, acquisitions, licensing, or other strategic transactions. LifeSci Capital will also advise the company on any restructuring of its liabilities. Quince stated that it does not intend to provide further updates unless a specific course of action is approved by its Board of Directors or further disclosure is deemed appropriate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content use","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL4C8Xd2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2610866506","title":"Quince Therapeutics Engages Lifesci Capital as Its Exclusive Financial Advisor to Explore Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2610866506","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610866506?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:05","pubTimestamp":1770671100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUA70VHLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2608818550","title":"Five Directors Resign from Quince Therapeutics Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2608818550","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608818550?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:31","pubTimestamp":1770067865,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. announced that Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray have resigned from the company's board of directors, effective January 30, 2026. The company stated that the resignations were not due to any disagreements related to company operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL6yw42B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2607024048","title":"Quince Therapeutics Cut to Hold From Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2607024048","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607024048?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:53","pubTimestamp":1769777580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QNCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2026 07:53 ET (12:53 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","QNCX","BK4007","BK4539"],"gpt_icon":0},{"id":"2607105682","title":"Quince Ends Development of Lead Drug Candidate; Shares Slide","url":"https://stock-news.laohu8.com/highlight/detail?id=2607105682","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607105682?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:52","pubTimestamp":1769719920,"startTime":"0","endTime":"0","summary":"Quince Therapeutics will end the development of its lead asset, a treatment for the neurodegenerative disorder ataxia-telangiectasia, after a pivotal Phase 3 trial failed to meet its expected outcomes.The drug candidate, dexamethasone sodium phosphate encapsulated in autologous erythrocytes, or eDSP, did not achieve statistical significance its primary and key secondary endpoints, the biotechnology company said Thursday afternoon.Shares for Quince nosedived to 27 cents a share ahead of the market close. The stock opened at $3.18 Thursday.Quince said cancelling the program would preserve cash and allow the company to explore available alternatives.\"We express our compassion and hope for future therapeutic options to the A-T community,\" Chief Executive Officer and Chief Medical Officer Dirk Thye said. \"We have tremendous gratitude toward the patients, their families, academic investigators and study sites, as well as all Quince employees, who worked so diligently over many years on this ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Quince Ends Development of Lead Drug Candidate; Shares Slide","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2607736055","title":"BUZZ-Quince Therapeutics drops after co's drug fails to meet main goal in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2607736055","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607736055?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:46","pubTimestamp":1769719589,"startTime":"0","endTime":"0","summary":"BUZZ-Quince Therapeutics drops after co's drug fails to meet main goal in late-stage trial** Shares of drug developer Quince Therapeutics QNCX.O down shares down 91.7% at 24 cents in afternoon trading","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nL4N3YU2ZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2607055263","title":"Quince down 14% after NEAT study endpoint did not reach statistical significance","url":"https://stock-news.laohu8.com/highlight/detail?id=2607055263","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607055263?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:30","pubTimestamp":1769718620,"startTime":"0","endTime":"0","summary":"Shares of Quince Therapeutics (QNCX) are down 44c, or 14%, to $2.75 after the company reported that the primary endpoint in the Phase 3 NEAT clinic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-down-14-after-neat-study-endpoint-did-not-reach-statistical-significance-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-down-14-after-neat-study-endpoint-did-not-reach-statistical-significance-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2607987055","title":"Quince Therapeutics trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2607987055","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607987055?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:10","pubTimestamp":1769717438,"startTime":"0","endTime":"0","summary":"15:06 EST Quince Therapeutics (QNCX) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","QNCX","BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"2607055580","title":"Quince Therapeutics Ends Development of eDSP After Phase 3 Trial Misses Key Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2607055580","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607055580?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:10","pubTimestamp":1769717414,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. announced topline results from its pivotal Phase 3 NEAT clinical trial evaluating dexamethasone sodium phosphate encapsulated in autologous erythrocytes  in patients with Ataxia-Telangiectasia (A-T). The trial did not achieve statistical significance for its primary and key secondary endpoints. eDSP was generally well tolerated, with no clinically meaningful safety concerns identified. Quince Therapeutics will cease clinical development of eDSP and intends to preserve cash and explore available options. The company has already presented these results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on Janu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL9lqyVn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2607555990","title":"Quince Therapeutics - to Cease Clinical Development of Edsp","url":"https://stock-news.laohu8.com/highlight/detail?id=2607555990","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607555990?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:10","pubTimestamp":1769717400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nTUABTSWYQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quincetx.com","stockEarnings":[{"period":"1week","weight":-0.3161},{"period":"1month","weight":-0.44},{"period":"3month","weight":-0.973},{"period":"6month","weight":-0.9407},{"period":"1year","weight":-0.9343},{"period":"ytd","weight":-0.9716}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0168},{"period":"3month","weight":-0.0052},{"period":"6month","weight":0.0481},{"period":"1year","weight":0.1654},{"period":"ytd","weight":-0.0023}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.091321},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.101646},{"month":3,"riseRate":0.428571,"avgChangeRate":0.079989},{"month":4,"riseRate":0.5,"avgChangeRate":-0.084014},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.087389},{"month":6,"riseRate":0.714286,"avgChangeRate":0.184618},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.077216},{"month":8,"riseRate":0.428571,"avgChangeRate":0.032954},{"month":9,"riseRate":0.571429,"avgChangeRate":0.013938},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.049658},{"month":11,"riseRate":0.571429,"avgChangeRate":0.199459},{"month":12,"riseRate":0.285714,"avgChangeRate":0.079276}],"exchange":"NASDAQ","name":"Quince Therapeutics, Inc.","nameEN":"Quince Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quince Therapeutics, Inc.,QNCX,Quince Therapeutics, Inc.股票,Quince Therapeutics, Inc.股票老虎,Quince Therapeutics, Inc.股票老虎国际,Quince Therapeutics, Inc.行情,Quince Therapeutics, Inc.股票行情,Quince Therapeutics, Inc.股价,Quince Therapeutics, Inc.股市,Quince Therapeutics, Inc.股票价格,Quince Therapeutics, Inc.股票交易,Quince Therapeutics, Inc.股票购买,Quince Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}